Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple breakfast replace the glucose drink for diabetes testing?

NCT ID NCT05789251

Diagnosis Sponsor: Centre Hospitalier Universitaire de la Réunion Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This trial explores whether a standardized breakfast and a continuous glucose monitor can replace the traditional glucose drink test for diagnosing diabetes and prediabetes in people with Dunnigan's lipodystrophy, a rare genetic condition that causes severe insulin resistance. The study will compare the breakfast test and sensor readings against the standard oral glucose tolerance test to see if they agree. If they do, it could offer a more comfortable and practical way to monitor these patients, potentially improving adherence to regular check-ups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Standardized breakfast and continuous interstitial glucose monitoring
What this could lead to
If successful, this could offer a more acceptable alternative to the standard glucose drink for diagnosing diabetes in people with Dunnigan's lipodystrophy, improving follow-up and early detection.
What could go wrong
This is a small, early-stage study. The breakfast may not match the glucose drink's accuracy, and continuous monitoring might not align perfectly with standard tests. Results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

54 people

The number who actually took part.

Started

Jun 2023

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject with Dunnigan's partial familial lipodystrophy followed at Reunion University Hospital not known to be diabetic. Aged 18 to 75 Having given their informed consent. Exclusion Criteria: * Diabetic patient Patient scheduled for scan within 7 days of freestyle placement protected persons: "pregnant woman, parturient, nursing mother, person deprived of liberty by judicial or administrative decision, minor, and person subject to a measure of legal protection: guardianship or curatorship)"

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dunnigan's partial familial lipodystrophy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

familial partial lipodystrophy, Dunnigan type lipodystrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lipodystrophy

Contacts and locations

Locations

  • Centre Hospitalier Universitaire de La Réunion

    Saint-Denis, 97400, Reunion

More trials for these conditions

Other studies related to the condition(s) this trial covers.